Breast Cancer Trial, Recruiting NCT07741435 Sponsor: Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo Condition: Breast Cancer
Back to Breast Cancer

Breast Cancer Trial, Recruiting

NCT07741435
Recruiting Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • Adults aged 18 years or older.
  • People who are willing and able to take part and provide blood, urine, and saliva samples, as well as basic personal information such as age, sex, race/ethnicity, and body weight category (BMI).
  • People who are able to sign a written consent form agreeing to take part and to allow their biological samples to be used for research.
  • People whose background characteristics (race, ethnicity, and BMI) are broadly comparable to other participants in the trial.
  • For the cancer group only: People who have received a confirmed cancer diagnosis within the 90 days before sample collection, supported by a biopsy and imaging to determine the stage of the cancer, and who have not had any cancer treatment at the time of collection or in the previous 3 years.
  • For the cancer-free (healthy) group only: People who have had no cancer diagnosis or cancer treatment in the previous 3 years, are not currently being investigated for suspected cancer, and do not have any clinical signs that a benign or uncertain tumor has progressed or become cancerous.
  • For the tumor-burden monitoring sub-study only: People with a biopsy-confirmed cancer diagnosis whose general physical functioning meets a specific performance threshold (confirm with trial site).

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who do not meet the general or group-specific criteria listed above.
  • People who are currently pregnant.
  • People who have had an organ transplant.
  • People who are currently taking or have taken certain medications that affect DNA chemistry (such as azacitidine or decitabine) or cytotoxic (cell-destroying) drugs, including those taken for autoimmune or inflammatory conditions.
  • People who have had, or are currently receiving, any form of cancer treatment beyond a diagnostic biopsy — including surgery for cancer, chemotherapy, targeted therapy, immunotherapy (including cancer vaccines), hormonal therapy, or radiotherapy.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 5 August 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +573016348173

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo
Registry
ClinicalTrials.gov
Start date
5 June 2025
Est. completion
4 June 2027

Where this trial is recruiting

🇨🇴 Colombia

Primary endpoints

Sensitivity of the Methylscape test for cancer-signal detection, as assessed against histopathological confirmation as the reference standard; Specificity of the Methylscape test for cancer-signal detection, as assessed against absence of cancer confirmed by medical-record review and 12-month follow-up

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 5 August 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov